Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Biogen Idec (NQ:BIIB)

222.82 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 63
Open 222.82
Bid (Size) 220.45 (100)
Ask (Size) 224.72 (100)
Prev. Close 222.82
Today's Range 222.82 - 222.82
52wk Range 138.00 - 230.49
Shares Outstanding 146,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
1 Profitable Stock Worth Investigating and 2 We Ignore
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
News headline image
Unpacking Q2 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Halozyme Therapeutics (NASDAQ:HALO) and its peers. O... 
Via StockStory
Topics Artificial Intelligence

Performance

YTD
+25.3%
+25.3%
1 Month
+3.1%
+3.1%
3 Month
+3.1%
+3.1%
6 Month
+25.6%
+25.6%
1 Year
+44.5%
+44.5%

More News

Read More
News headline image
Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack
Via StockStory
Topics Artificial Intelligence
News headline image
Winners And Losers Of Q2: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
Reflecting On Therapeutics Stocks’ Q2 Earnings: AbbVie (NYSE:ABBV)
Via StockStory
Topics Artificial Intelligence
News headline image
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience ↗
Via MarketBeat
News headline image
Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology ↗
Via MarketBeat
Thursday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest
Via StockStory
Topics Artificial Intelligence
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
Via Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
Via Investor Brand Network
News headline image
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
From BioMedWire
Via GlobeNewswire
News headline image
Therapeutics Stocks Q2 Recap: Benchmarking Myriad Genetics (NASDAQ:MYGN)
Via StockStory
Topics Artificial Intelligence
News headline image
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
From Biogen Inc.
Via GlobeNewswire
News headline image
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
From Biogen Inc.
Via GlobeNewswire
News headline image
Q2 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
Unpacking Q2 Earnings: Novavax (NASDAQ:NVAX) In The Context Of Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
3 Reasons to Sell BIIB and 1 Stock to Buy Instead
Via StockStory
Topics Artificial Intelligence Stocks
News headline image
Therapeutics Stocks Q2 Results: Benchmarking BioMarin Pharmaceutical (NASDAQ:BMRN)
Via StockStory
Topics Artificial Intelligence

Frequently Asked Questions

Is Biogen Idec publicly traded?
Yes, Biogen Idec is publicly traded.
What exchange does Biogen Idec trade on?
Biogen Idec trades on the Nasdaq Stock Market
What is the ticker symbol for Biogen Idec?
The ticker symbol for Biogen Idec is BIIB on the Nasdaq Stock Market
What is the current price of Biogen Idec?
The current price of Biogen Idec is 222.82
When was Biogen Idec last traded?
The last trade of Biogen Idec was at 10/01/26 04:00 PM ET
What is the market capitalization of Biogen Idec?
The market capitalization of Biogen Idec is 32.71B
How many shares of Biogen Idec are outstanding?
Biogen Idec has 33B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.